Clinical Proteomics

Scope & Guideline

Pioneering Discoveries in Clinical Proteomics

Introduction

Welcome to your portal for understanding Clinical Proteomics, featuring guidelines for its aims and scope. Our guidelines cover trending and emerging topics, identifying the forefront of research. Additionally, we track declining topics, offering insights into areas experiencing reduced scholarly attention. Key highlights include highly cited topics and recently published papers, curated within these guidelines to assist you in navigating influential academic dialogues.
LanguageEnglish
ISSN1542-6416
PublisherBMC
Support Open AccessYes
CountryUnited Kingdom
TypeJournal
Converge2004, from 2006 to 2024
AbbreviationCLIN PROTEOM / Clin. Proteom.
Frequency1 issue/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressCAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND

Aims and Scopes

The journal 'Clinical Proteomics' is dedicated to advancing the field of clinical proteomics, emphasizing the application of proteomic technologies in understanding disease mechanisms, identifying biomarkers, and improving patient outcomes. It covers a broad spectrum of research involving proteomic analyses across various clinical scenarios.
  1. Clinical Applications of Proteomics:
    The journal focuses on the application of proteomic technologies to discover and validate biomarkers for disease diagnosis, prognosis, and therapeutic monitoring across a variety of conditions, including cancer, cardiovascular diseases, and autoimmune disorders.
  2. Innovative Methodologies:
    It emphasizes the development and application of innovative proteomic methodologies, such as mass spectrometry and data-independent acquisition techniques, which enhance the sensitivity and specificity of protein analysis in clinical samples.
  3. Interdisciplinary Research:
    The journal encourages interdisciplinary research that combines proteomics with other omics technologies (genomics, transcriptomics, and metabolomics) to provide a comprehensive understanding of disease biology and facilitate personalized medicine.
  4. Biomarker Discovery and Validation:
    A significant focus is on the discovery and validation of novel protein biomarkers that can aid in the early detection of diseases, monitor disease progression, and predict treatment responses.
  5. Patient-Centric Studies:
    Clinical Proteomics often publishes studies that directly involve patient samples, reflecting real-world clinical scenarios to ensure that findings are applicable and beneficial to patient care.
The journal has seen a rise in interest in several emerging themes, reflecting the evolving landscape of clinical proteomics and the increasing integration of technological advancements in research.
  1. Proteomics in Cancer Research:
    There is a notable trend in the application of proteomics to cancer research, particularly in understanding tumor heterogeneity, resistance mechanisms, and the identification of novel biomarkers for early detection and targeted therapy.
  2. Integration of Multi-Omics Approaches:
    Emerging studies are increasingly integrating proteomics with genomics and metabolomics, allowing for a more comprehensive understanding of biological systems and disease mechanisms, enhancing predictive modeling and personalized medicine.
  3. Machine Learning and Bioinformatics in Proteomics:
    The utilization of machine learning and advanced bioinformatics tools to analyze complex proteomic datasets is growing, enabling researchers to uncover patterns that can lead to new insights in disease pathology and treatment responses.
  4. Non-Invasive Biomarker Discovery:
    There is a heightened focus on non-invasive proteomic biomarkers derived from bodily fluids (e.g., saliva, urine), which are crucial for developing diagnostic tools that are easier to implement in clinical settings.
  5. COVID-19 Related Proteomics:
    The ongoing research related to COVID-19 has led to a surge in publications that explore the proteomic landscape of the virus and its effects on the human body, highlighting the importance of proteomics in understanding infectious diseases.

Declining or Waning

While 'Clinical Proteomics' continues to expand in several areas, certain themes have shown a decline in frequency or prominence in recent publications. These waning scopes may reflect shifts in research priorities or advancements in technology that have rendered some topics less relevant.
  1. Basic Research without Clinical Relevance:
    Research focusing solely on basic proteomic techniques without direct application to clinical issues has decreased, as there is a growing preference for studies that link proteomics directly to clinical outcomes.
  2. Single Omics Studies:
    There has been a decline in publications that focus exclusively on proteomics without integrating other omics approaches, as the trend shifts towards more holistic, multi-omics strategies that provide a more comprehensive view of disease.
  3. Traditional Biomarker Approaches:
    The reliance on traditional biomarker discovery approaches, which often do not incorporate advanced proteomic technologies, has waned in favor of more innovative and sophisticated methodologies that offer greater sensitivity and specificity.
  4. Non-Quantitative Proteomics Studies:
    The frequency of studies employing qualitative proteomic analyses has decreased, as the field increasingly values quantitative approaches that provide measurable and reproducible results.

Similar Journals

Molecular Omics

Bridging Disciplines for Tomorrow's Discoveries
Publisher: ROYAL SOC CHEMISTRYISSN: Frequency: 6 issues/year

Molecular Omics is a premier, peer-reviewed journal published by the Royal Society of Chemistry, focusing on the interdisciplinary field of molecular biology with significant implications for biochemistry and genetics. With an E-ISSN of 2515-4184, this journal has been dedicated to disseminating high-quality research since its inception in 2018, maintaining an impressive trajectory in academic contributions until 2024. Currently, it holds a Q2 quartile ranking in both Biochemistry and Genetics, alongside a Q3 ranking in Molecular Biology for 2023, highlighting its relevance and influence in these domains. The journal is accessible as an open access publication, promoting the widespread dissemination of groundbreaking research. As part of a vibrant academic community, Molecular Omics aims to bridge fundamental and applied science, appealing to researchers, professionals, and students eager to expand their knowledge on molecular mechanisms and technologies that shape the future of biological research.

Biomarker Insights

Transforming health insights through groundbreaking research.
Publisher: SAGE PUBLICATIONS LTDISSN: 1177-2719Frequency: 1 issue/year

Biomarker Insights, published by SAGE Publications Ltd, is a leading open-access journal dedicated to advancing the field of biomarker research and its applications in health and disease. With an ISSN of 1177-2719 and an E-ISSN of 1177-2719, this journal has been at the forefront of disseminating high-quality scientific findings since its inception in 2006. Based in New Zealand, it has achieved a notable impact within the academic community, ranking in Q2 for Biochemistry (medical) and Molecular Medicine, and Q1 in Pharmacology as of 2023. This positions Biomarker Insights as a critical resource for researchers, professionals, and students alike, looking to explore innovative methodologies and applications in biomarker discovery and validation. With a commitment to open access, the journal ensures that groundbreaking research is readily available to the global community, fostering collaboration and innovation in the ever-evolving field of biomedical sciences.

MASS SPECTROMETRY REVIEWS

Empowering Research Through Peer-Reviewed Insights
Publisher: WILEYISSN: 0277-7037Frequency: 6 issues/year

MASS SPECTROMETRY REVIEWS, published by Wiley, is a premier academic journal dedicated to advancing the field of mass spectrometry and its applications across a multitude of scientific disciplines. With an ISSN of 0277-7037 and an E-ISSN of 1098-2787, the journal has established itself as a vital resource within the realms of Analytical Chemistry, Biochemistry, Genetics, Condensed Matter Physics, and Spectroscopy, achieving Q1 status across these categories in 2023. As a testament to its significant contribution to scholarly research, it boasts impressive Scopus rankings, including a rank of #2 out of 76 in Chemistry - Spectroscopy and #4 out of 156 in Chemistry - Analytical Chemistry, placing it in the 97th percentile and above. Emphasizing high-quality, peer-reviewed research, MASS SPECTROMETRY REVIEWS serves as an essential platform for researchers, professionals, and students aiming to stay abreast of cutting-edge developments and methodologies in mass spectrometry. The journal is committed to fostering a deeper understanding of mass spectrometric techniques while also contributing to interdisciplinary advancements, making it a valuable addition to any academic library. Authors seeking to disseminate their work in a journal with a strong reputation and impact in the scientific community will find MASS SPECTROMETRY REVIEWS an ideal venue.

Current Proteomics

Navigating the Evolving Landscape of Proteomics
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1570-1646Frequency: 5 issues/year

Current Proteomics is a distinguished journal dedicated to the dynamic field of proteomics, offering researchers and professionals a platform to disseminate innovative findings and comprehensive reviews. Published by Bentham Science Publishers Ltd, this journal caters to a global audience and serves as an essential resource for students, academics, and industry experts interested in advances in biochemistry and molecular biology. With an ISSN of 1570-1646 and an E-ISSN of 1875-6247, the journal has established itself in various research categories, achieving a Q4 ranking in both Biochemistry and Molecular Biology as of 2023. While the impact factor and H-index data are not specified, its Scopus ranking reflects a competitive position in its fields, with percentiles in the 12th to 16th range. Although not an open-access journal, Current Proteomics is vital for fostering ongoing dialogue and collaboration in proteomic research, encouraging contributions that explore cutting-edge methodologies and applications. Researchers are invited to share their insights and contribute to this evolving discipline, thus enhancing the collective understanding of proteomics within the scientific community.

Biomarkers in Medicine

Unlocking the Potential of Biomarkers in Healthcare
Publisher: FUTURE MEDICINE LTDISSN: 1752-0363Frequency: 24 issues/year

Biomarkers in Medicine is a prominent academic journal dedicated to advancing the field of medical biochemistry and drug discovery. Published by Future Medicine Ltd in the United Kingdom, this journal aims to provide a platform for researchers, clinicians, and biotechnology professionals to share their findings on the critical role of biomarkers in diagnosis, treatment, and prognosis of various diseases. With a focus on high-quality, peer-reviewed research, Biomarkers in Medicine supports the dissemination of innovative approaches and therapeutic developments across its converged publication years from 2008 to 2024. Rated in the Q3 category for biochemistry (medical), clinical biochemistry, and drug discovery, it occupies a significant place in its field, attracting contributions that push the boundaries of knowledge and application. Although it does not offer open access, the journal remains committed to excellence and rigor in the representation of ground-breaking studies, making it an essential resource for scholars and professionals eager to stay at the forefront of biomarker research.

Genome Medicine

Unlocking the Secrets of Genetic Disorders
Publisher: BMCISSN: 1756-994XFrequency: 1 issue/year

Genome Medicine is a prestigious, peer-reviewed journal published by BMC, focusing on the rapidly evolving fields of genetics, molecular biology, and molecular medicine. Established in 2009 and boasting an open-access format, it has become a leading platform for disseminating high-quality research findings that advance our understanding of genetic diseases and therapeutic innovations. With an impressive Q1 ranking across multiple relevant categories—in particular, genetics (clinical), molecular biology, and molecular medicine—this journal is recognized for its substantial impact in the academic community, as evidenced by its exceptional placement in Scopus rankings. By providing unrestricted access to groundbreaking studies, Genome Medicine fosters collaboration and knowledge sharing among researchers, clinicians, and educators, thus playing a vital role in the transition from fundamental genetic research to clinical applications. Researchers are encouraged to contribute their findings and insights, further solidifying the journal’s position as a pivotal resource for those dedicated to advancing genomic medicine.

Cancer Informatics

Empowering Oncology Through Informatics
Publisher: SAGE PUBLICATIONS LTDISSN: Frequency: 1 issue/year

Cancer Informatics, published by SAGE PUBLICATIONS LTD, is a leading open-access journal dedicated to the integration of computational techniques and cancer research. Since its inception in 2005, this journal has become a vital resource for researchers, professionals, and students interested in the intersection of informatics and oncology. With an E-ISSN of 1176-9351 and a focus on the innovative application of data analysis in cancer research, Cancer Informatics serves to disseminate critical findings that aid in understanding cancer biology and enhancing treatment modalities. Recognized in the Q3 category for both Cancer Research and Oncology according to the 2023 metrics, it currently holds a Scopus ranking of #246 in Medicine _ Oncology and #172 in Biochemistry, Genetics and Molecular Biology _ Cancer Research, indicating its contribution to ongoing research in these fields. This journal not only supports open access to scientific findings but also aims to foster collaboration among interdisciplinary scholars worldwide, making it an essential platform for advancing the field of cancer informatics through cutting-edge research and innovative methodologies.

RAPID COMMUNICATIONS IN MASS SPECTROMETRY

Advancing the frontiers of mass spectrometry research.
Publisher: WILEYISSN: 0951-4198Frequency: 24 issues/year

RAPID COMMUNICATIONS IN MASS SPECTROMETRY is a leading journal published by Wiley, focusing on the rapidly evolving field of mass spectrometry and its applications across various domains, including analytical, organic, and spectroscopy chemistry. With its ISSN 0951-4198 and an E-ISSN of 1097-0231, the journal has firmly established itself as a reputable source of innovative research since its inception in 1987, and is set to continue until 2024. As evidenced by its 2023 Scopus rankings, the journal occupies a solid position in the realms of analytical chemistry (Q3), organic chemistry (Q3), and spectroscopy (Q3), reflecting its impact among a diverse audience of researchers and professionals. Although it is not an open-access publication, the findings shared within its pages are pivotal for advancing knowledge and practical applications in mass spectrometry, making it an essential resource for students and experts aiming to stay abreast of the latest scientific developments.

EUROPEAN JOURNAL OF MASS SPECTROMETRY

Exploring Innovative Frontiers in Mass Spectrometry
Publisher: SAGE PUBLICATIONS LTDISSN: 1469-0667Frequency: 6 issues/year

European Journal of Mass Spectrometry, published by SAGE Publications Ltd, is a premier academic journal dedicated to advancing the field of mass spectrometry and its applications in atomic, molecular physics, and medical sciences. With an ISSN of 1469-0667 and an E-ISSN of 1751-6838, this journal serves as a vital platform for disseminating innovative research findings and methodologies that enhance our understanding of complex molecular structures and interactions. Operating from the United Kingdom, it has established itself within the academia by achieving a Q3 ranking in several categories, including Atomic and Molecular Physics and Spectroscopy, as per the 2023 category quartiles. Researchers and professionals can access a diverse range of articles that not only address theoretical aspects but also practical applications in various scientific disciplines. As the field continues to evolve, the European Journal of Mass Spectrometry plays a crucial role in fostering collaboration and knowledge sharing among experts, making it an indispensable resource for anyone invested in mass spectrometry and its interdisciplinary connections.

Proteomes

Bridging Disciplines Through Protein Research.
Publisher: MDPIISSN: Frequency: 4 issues/year

Proteomes, published by MDPI since 2013, is a notable open access journal that occupies a critical place in the realms of Biochemistry, Clinical Biochemistry, Molecular Biology, and Structural Biology. Based in Switzerland, this journal not only promotes the dissemination of high-quality research pertaining to protein structures and functions but also emphasizes interdisciplinary approaches that bridge various fields of biomedical science. With a Category Quartile ranking of Q2 across multiple pertinent categories in 2023, Proteomes boasts a competitive impact within the scientific community, evidenced by its robust Scopus rankings. Researchers, professionals, and students are invited to explore a wealth of pioneering studies and reviews that are made freely accessible, aligning with global trends in open scientific communication. Whether contributing original research or seeking to expand their knowledge, the journal serves as an invaluable resource for anyone engaged in the evolving landscape of proteomics.